| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 10,085 | 9,389 | ||
| General and administrative | 3,831 | 4,333 | ||
| Total operating expenses | 13,916 | 13,722 | ||
| Loss from operations | -13,916 | -13,722 | ||
| Interest income, net | 2,101 | 1,407 | ||
| Other expense, net | -2 | -7 | ||
| Interest expense | 0 | 0 | ||
| Total other income, net | 2,099 | 1,400 | ||
| Loss before income taxes | -11,817 | -12,322 | ||
| Income tax benefit | -15 | -21 | ||
| Net loss | -11,802 | -12,301 | ||
| Earnings per share basic | -0.08 | -0.09 | ||
| Earnings per share diluted | -0.08 | -0.09 | ||
| Weighted average number of diluted shares outstanding | 145,104,986 | 130,350,391 | ||
| Weighted average number of shares outstanding basic | 145,104,986 | 130,350,391 | ||
Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI)